A few successful examples document promise of such approaches: RT plus androgen deprivation to treat locally advanced prostate cancer or RT plus cetuximab, an inhibitory antibody against the epidermal growth factor receptor (EGFR), to treat head and neck cancer patients not tolerating concurrent cisplatin chemotherapy (CT) [26,27,28,29] and more recently, immunotherapy [30,31]. This evidence concerns the gene EGFR and Familial prostate cancer.